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Strategic Planning and Costs of FDA Regulation
Summary
• The regulatory burden for medical device innovation varies based on the specific Food and Drug
Administration (FDA) pathway required, and early strategic planning for this regulatory burden is
critical.
• The regulatory strategy and milestones must be integrated with other key components of the
innovation process and informed by an understanding of and/or direct communication with all the
stakeholders involved, including the customer, engineering/manufacturing team, research and
development team, safety/regulatory bodies, the potential payers, and investors.
• While it is almost never too early to initiate contact with the FDA, inquiries through 513(g) petitions
or pre-submission meetings should be focused on specific questions and goals to make the most of
these engagements.
• Regulatory assessments and consultation with experts require upfront costs, but saving time and
money in the long term by designing an efficient regulatory strategy can be the difference between
success and failure for the academic entrepreneur.
• Fundraising (private and public) must be considered in the regulatory strategy, as approximately 90%
of fundraising is based on claims tied to regulatory milestones.
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Topic Relevance by Timeline 
Summary 
● The regulatory burden for medical device innovation varies based on the specific Food and 
Drug Administration (FDA) pathway required, and early strategic planning for this regu-
latory burden is critical. 
● The regulatory strategy and milestones must be integrated with other key components of 
the innovation process and informed by an understanding of and/or direct communication 
with all the stakeholders involved, including the customer, engineering/manufacturing 
team, research and development team, safety/regulatory bodies, the potential payers, and 
investors. 
● While it is almost never too early to initiate contact with the FDA, inquiries through 513(g) 
petitions or pre-submission meetings should be focused on specific questions and goals to 
make the most of these engagements.  
● Regulatory assessments and consultation with experts require upfront costs, but saving 
time and money in the long term by designing an efficient regulatory strategy can be the 
difference between success and failure for the academic entrepreneur. 
● Fundraising (private and public) must be considered in the regulatory strategy, as approx-
imately 90% of fundraising is based on claims tied to regulatory milestones. 
Introduction 
Regulatory strategy is a critical component of the medical device innovation process, and early 
development of an effective regulatory plan can be the difference between success and failure for 
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the academic entrepreneur. The regulatory burden, including time, clinical evidence, and costs, 
varies based on the required FDA regulatory pathway, which itself is mainly determined by the 
medical device class and the novelty of the device. In addition, the regulatory strategy should align 
with reimbursement and regulatory claims needed for commercial success. A well thought-out 
regulatory strategy allows for the creation of a realistic roadmap for medical device development, 
and this strategy works best when integrated with the other core components of the innovation 
process, including research and development, engineering, sales, reimbursement, and marketing 
strategies. While the regulatory strategy establishes a foundation for these other core components, 
the other components also inform the regulatory strategy, and success often depends on consider-
ation of this interaction at an early point in the innovation process.  
Consider the Stakeholders  
Successful medical devices must speak to all involved stakeholders. This simple concept is 
critically important when considering medical device development and assessing the feasibility of 
device technology. Stakeholders in medical device innovation include the customer, marketing 
specialists, the engineering and manufacturing team, safety/regulatory bodies, the payer, and 
investors. Each stakeholder has unique goals and considerations. An academic entrepreneur must, 
therefore, look at the product through the perspective of each party and be able to tell a different 
facet of the story to each group of stakeholders. For instance, the customers need to understand the 
benefit of the device and why they should be interested in it from a healthcare standpoint, while 
the engineering and manufacturing team needs to consider the claims for regulatory approval, such 
that the device technology meets FDA requirements. For the payer, the academic entrepreneur will 
have to speak to why the device is necessary—does the device decrease morbidity or save 
healthcare costs? Innovators will want to know the key innovation of the device, how the innova-
tion is protected (i.e., intellectual property, especially patents), and the exit strategy.  
 
The successful academic entrepreneur must be able to tell these different stories and consider the 
entire life cycle of the device innovation process, from premarket to post-market. While the focus 
of this chapter will be on navigating the FDA regulatory pathways, the complexity of having 
multiple stakeholders becomes compounded when the market strategy involves a global approach 
rather than a domestic one. In these situations, the academic entrepreneur will need to consider 
each country’s stakeholders and unique laws, regulatory processes, and healthcare systems in order 
to successfully launch a medical device in each desired country.  
Building a Team  
While it is possible to gain expertise in any domain of the medical device development process, 
becoming a true expert in all facets of the process is likely impossible. For this reason, the aca-
demic entrepreneur must build an experienced team around them with members from each domain 
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who understand the process (see the chapter “Building a Successful Startup Team”). This core 
team must be an integrated, flexible, collaborative team that covers core strategic functions (i.e., 
clinical, regulatory, legal, research and development, reimbursement, engineering, sales, and mar-
keting) (Goldenberg and Gravagna). Communication across the team is critical to success, and 
also important for potential investors. Projects where engineers work together with the regulatory 
team are more successful than those in which engineers design devices or products independently 
of regulatory concerns. This team will also serve to improve the chances of fundraising success, 
as the quality of the team is a core component of a good investor’s decision-making process.  
 
For an academic entrepreneur, an early key to success is to identify groups and/or centers at their 
academic institution that specialize in innovation (see the chapter “Resources at Academic 
Entrepreneurship Centers”). The past two decades have seen a rise in the focus on entrepreneurship 
at academic medical institutions across the U.S., as these centers are uniquely positioned with 
access to biomedical research, technology, and potential users of innovation (patients and physi-
cians) (Toner and Tompkins). While the terminology may differ across academic research 
institutions, these offices often have engineers and staff with technology transfer and regulatory 
expertise (i.e., centers or offices for innovation or entrepreneurship) (see the chapter “Working 
with the University Technology Transfer Office”). Furthermore, engaging with these offices or 
centers is free for the academic entrepreneur and can save valuable time and money.  
 
Another option is to hire, or in some cases partner with, a private commercialization organization, 
such as a contract research organization or innovation center. The academic entrepreneur must 
recognize that these organizations and companies offer a range of services, from focused consult-
ing services (i.e., prototype development) to one-stop-shop integrated programs that combine 
multiple domains. Some companies have incubator or accelerator programs that take advantage of 
a collaborative environment to facilitate interactions between the technical and business sides of 
device development (see the chapter “Accelerators and Incubators”). Once again, identifying these 
potential partners and contacting them early in the process is extremely important. The costs for 
hiring these organizations depend on the services required and the level of detail needed.  
Regulatory Considerations  
The regulatory strategy for device innovation is based on device classification and the required 
pathway as determined by the FDA (see the chapter on “FDA Device Regulation: 510(k), PMA”). 
Determining the appropriate pathway early is essential to establishing a rough estimate of the 
amount of time and money that will be required to bring the product to the market. Early and 
frequent contact with a regulatory expert consultant is crucial for the successful navigation of a 
new medical device through the FDA regulatory process.  
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First and foremost, the academic entrepreneur must consider if the device is under FDA regulation, 
as some devices may be outside of the FDA’s jurisdiction and therefore do not need FDA clear-
ance. Realizing this early can safe unnecessary time and money. To facilitate the academic 
entrepreneur in making this determination, the FDA has important information on its website—a 
searchable database of devices and classes, as well as a formal inquiry process called the 513(g) 
petition (Center for Devices and Radiological Health, Procedures for Section 513(g) Requests for 
Information - Guidance; Center for Devices and Radiological Health, “Is The Product A Medical 
Device?”). Through this petition, the academic entrepreneur can ask the FDA to consider a product 
and make a formal determination as to whether that product is a medical device or not, based on 
the FDA’s definition; additionally, the FDA will often provide a device classification and 
regulatory requirements for products deemed to be medical devices. Thus an academic entrepre-
neur can utilize this process to determine the least burdensome regulatory pathway for a proposed 
device. The current standard fee for each 513(g) petition is $4,349, and the FDA is required to 
respond within 60 days of receipt of the formal written request (Center for Devices and 
Radiological Health, “Medical Device User Fee Amendments (MDUFA) User Fees”). 
 
Once the academic entrepreneur has determined that a product is a medical device, the next step 
is to assess the potential FDA regulatory pathway. Identifying the correct pathway early is critical 
to set milestones, plan necessary preclinical and clinical trials, estimate cost requirements, deter-
mine fundraising goals, and create a realistic timeline for all stakeholders for when the product 
may reach the market. As mentioned above, the FDA website allows searching for similar 
products, which can be used as a foundation for the potential regulatory pathway. Findings similar 
devices or predicates offers valuable guidance to the academic entrepreneur by helping to establish 
a route to market and identifying standard and special controls and requirements.  
 
The FDA also allows and encourages early contact from academic entrepreneurs and innovators 
through the use of pre-submission meetings, also called “Q-sub” or “pre-sub” (Center for Devices 
and Radiological Health, “Feedback and Meetings for Device Submissions: The Q-Submission 
Program”). These meetings, which are described in the chapter on FDA regulation, can be 
requested prior to submitting an application to the FDA and range from informational sessions to 
discussions of specifics in regards to application preparation or protocol development for studies. 
While the FDA will never give an official approval of the regulatory plan or device itself in a Q-
sub meeting, obtaining early feedback from the FDA can allow for necessary changes or 
modifications to the regulatory strategy and provide long-term savings in cost and time.  
FDA Application Costs 
First established in 2002, medical device user fees are required for all pre-market application sub-
missions, as well as when companies register their facility or list their devices with the FDA. The 
fees are standardized by application type and by fiscal year as part of the “Medical Device User 
Fee Amendments” (MDUFA) published on the FDA website (Center for Devices and Radiological 
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Health, “Medical Device User Fee Amendments (MDUFA) User Fees”). Additionally, there are 
two separate fees for each application type: standard and small business. To qualify as a small 
business, a company must have an approved small business determination (SBD) from the FDA 
and gross receipts or sales of less than $30 million. Small businesses are also eligible to have their 
first premarket approval (PMA) application fee waived. For FY2019, the standard fee for 510(k) 
submissions is $10,953, while the fee for small businesses is $2,738 (Center for Devices and 
Radiological Health, “Medical Device User Fee Amendments (MDUFA) User Fees”). For the de 
novo 510(k), these user fees are $96,644 and $24,161 for standard applicants and small businesses, 
respectively (Center for Devices and Radiological Health, “Medical Device User Fee Amendments 
(MDUFA) User Fees”). The PMA application is the most expensive and costs $322,147 for a 
standard application or $80,537 for a small business (Center for Devices and Radiological Health, 
“Medical Device User Fee Amendments (MDUFA) User Fees”). As discussed in the previous 
section, these application fees are strictly the costs paid to the FDA with each submission and do 
not take into account the cost of device development and research studies. Another important point 
to remember is that pre-submission or Q-sub applications and requests are free. Note that any 
510(k) or PMA application for a device intended solely for pediatric use is exempt from user fees. 
However, if one wants to change the intended use of a device from pediatric to adult, this requires 
a new 510(k) or PMA application and is subject to user fees. 
Strategies for Each Specific FDA Regulatory Pathway 
When the appropriate FDA regulatory pathway is determined, the next step is to plan an effective 
and integrated strategy to fulfill the regulatory requirements. For instance, applications for a 510(k) 
submission are often thousands of pages or more, while the PMA applications are often tens of 
thousands of pages. Additionally, PMA applications cost more and often require lengthy clinical 
trials, which may not be needed for a 510(k). The costs include not only those of the application 
itself but also the costs of the appropriate bench studies, preclinical studies, and clinical trials, if 
necessary (see the chapter “FDA Device Regulation: 510(k), PMA”). According to a survey of 
over 200 medical technology companies conducted by Makower et al., every additional month 
(i.e., for FDA inefficiencies or unforeseen delays) spent attempting to work through the 510(k) or 
PMA process costs a company/academic entrepreneur more than $520,000 and $740,000, respec-
tively (Makower et al.). Therefore, the commercialization plan for a device must incorporate an 
understanding of the regulatory component, and the academic entrepreneur must consider the 
specifics for each pathway, including estimates of the time and costs involved.  
 
Investigational Device Exemption  
For new devices that present more than a nonsignificant risk, an Investigational Device Exemption 
(IDE) is required before the device can be used in clinical studies to collect safety and efficacy 
data, which will later be used in support of a 510(k) or premarket approval (PMA) application. 
The academic entrepreneur will be required to present the IDE number to the academic research 
institution’s internal review board (IRB) for protocol approval before the device can be studied 
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clinically. One important point about the IDE is that it is not required for nonsignificant risk de-
vices as they do not pose significant risks to human subjects. Nonsignificant risk devices still 
require IRB approval prior to starting a clinical trial, and the investigators must comply with an 
abbreviated set of IDE requirements, including proper labeling, obtaining informed consent, and 
safety monitoring. The FDA has published a guide to distinguishing between significant and 
nonsignificant risk devices, which can be reviewed freely on the FDA website (Office of the 
Commissioner). 
 
The application for an IDE includes a description of the device and all previous testing, including 
preclinical or clinical (if available) and bench data, and the FDA will respond with an IDE number 
upon receipt. As per the FDA, the IDE application is considered approved 30 days after its receipt 
if the investigator receives no email or correspondence stating that the application was disap-
proved. These applications can be from a few hundred pages up to several thousand pages, 
including a detailed protocol and plan for biostatistical analysis. Overall, the costs from beginning 
the application to obtaining an IDE can range from tens of thousands of dollars to even millions, 
but the average is ~$40,000.  
 
510(k)  
Devices that go through the 510(k) pathway must be at least as safe and effective as an approved 
device (i.e., a predicate). The new device must be substantially equivalent to the predicate, and the 
predicate device must also have gone through the 510(k) process. The academic entrepreneur must 
remember that selecting predicates and identifying intended uses for the new device are critical 
points in the regulatory process. A device that is cleared with a 510(k) can only be marketed based 
on the intended use, and claims are often limited by the uses of the substantially equivalent predi-
cate device. Therefore, a regulatory strategy that includes broad descriptions of the device and 
intended use are preferable compared to a very narrow 510(k) application, in terms of the 
marketability and commercialization of the device. The 510(k) pathway is frequently used by 
many companies, but, by definition of the pathway, it is challenging to differentiate the product 
from others. 
 
A 510(k) application can also be used when changing the indication for use of a previously cleared 
device (i.e., expanding a previously cleared intravenous device for intra-arterial use) and when 
proposing a significant modification to a previously cleared device. These additional uses are 
important to consider, as in some cases an academic entrepreneur may be able to do a series of 
510(k)s for a few million each, instead of a lengthy PMA that may cost over $100 million. 
  
While the application processing fee to the FDA is relatively cheap (see the section above on 
application costs), the survey by Makower et al. revealed that the mean cost to bring a 510(k) 
product from concept to clearance was $31 million, with 77% of that money spent on FDA-related 
activities (Makower et al.). The same survey found that the mean time from first filing to clearance 
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for a 510(k) application was 10 months, while the time from first communication with the FDA to 
clearance was 31 months (Makower et al.). 
 
PMA  
PMA applications are required for almost all class III devices and for those devices without an 
existing predicate. This regulatory pathway is more likely to require animal and clinical data, 
although these data are becoming increasingly required for 510(k) devices as well. Given the 
lengthy and costly process of the PMA pathway, it is essential to manage the associated risks 
through monitoring study outcomes and proactively discussing test failures or data issues with the 
FDA. Manufacturing and quality systems must also be audited prior to PMA clearance. This is 
important to consider when identifying manufacturing and commercialization partners, as organi-
zations with product experience but not necessarily medical device experience may not have the 
appropriate quality systems and controls in place as required by the FDA.  
 
The Makower et al. survey found that the mean cost from concept to approval for a PMA product 
was $94 million, again with over 75% of the money spent on steps related to the FDA regulatory 
process (Makower et al.). Mean time from first communication with the FDA to PMA approval 
was 54 months. Interestingly, the same survey found that time from first communication to obtain-
ing the Conformité Européenne (“European conformity,” or CE) mark from the European Union’s 
regulatory body for PMA-type products was only 11 months. While this faster approval by the CE 
may be enticing to the academic entrepreneur in terms of regulatory strategy, they must remember 
that even with the CE mark there is no guarantee the device will be accepted widely by physicians 
in different EU countries or that the device will be reimbursed by each EU country (Van Norman). 
These tradeoffs could potentially lead to increased time and costs compared to going through the 
longer FDA process with its benefits of marketing and obtaining reimbursement in a more con-
sistent manner in a single country. 
Fundraising and Regulatory Milestone Planning 
A well-developed regulatory strategy must also consider fundraising and the cost requirements at 
each step. To develop an appropriate set of regulatory milestones for a potential device, the 
academic entrepreneur can refer to the FDA website for the required data for 510(k) or PMA 
applications. For 510(k) devices these milestones often include: 1) prototyping and design, 2) 
preclinical studies including bench, wet-lab, and animal (if needed) results, 3) submitting 510(k) 
application, 4) application approval, and 5) post-market studies (Figure 1). For PMA products the 
milestones include the addition of more robust clinical studies: 1) prototyping and design, 2) 
preclinical studies including bench, wet-lab, and animal (if needed) results, 3) obtaining IDE and 
performing first-in-humans study, 4) pivotal clinical trial (often randomized controlled trial), 5) 
submitting PMA application, 6) application approval, and 7) post-market studies (Figure 2).  
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Figure 1. Timeline of Regulatory Milestones for 510(k). 
 
 
Figure 2. Timeline of Regulatory Milestones for PMA. 
 
 
Tying regulatory milestones to fundraising series can help the academic entrepreneur plan an 
appropriate timeline and understand the points at which an infusion of money will be necessary to 
reach the next stage. Furthermore, unexpected or negative results from an early step or failure to 
achieve a milestone can prevent overspending funds on a device that may never make it to market. 
Importantly, approximately 90% of fundraising is based on claims tied to regulatory milestones. 
When approaching potential investors (i.e., government departments, private foundations, venture 
capitalists (VC), or angel investors) it is always better to ask for $5 million once than for $1 million 
five times, since each request can potentially lead to more dilution of equity (see the chapters 
“Seeking Venture Capital Investments” and “Angel Investors”).  
 
The academic entrepreneur must also remember that government funding is often slower (up to 18 
months from submitting an application to receiving funds), but private funders, such as VCs, 
expect a return on their investment, want quicker turnarounds, and hate surprises, especially 
unexpected regulatory burdens or hurdles. Therefore, early FDA engagement so the academic 
entrepreneur can estimate the total cost to market at the beginning is crucial for VCs. Investors 
want to know that there is an appropriate regulatory strategy in which the pathway is defined and 
relatively smooth from prototype to market.  
 
In today’s medical device innovation landscape, early VC investment rarely exists, and instead 
many entrepreneurs and companies are searching for angel investing for prototyping and initial 
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preclinical and feasibility studies. After this initial round of funding, the next round requires pur-
suing regulatory clearance through additional studies and development of the core team. After 
regulatory approval, another funding round is often required for commercialization and for build-
ing sales and manufacturing teams.  
Consulting with Regulatory Experts 
The importance of early and frequent contact with regulatory experts cannot be overstated. 
Regulatory consultation can come in several forms, from large experienced consulting companies 
to independent consultants. The same consulting company may even work on competing technol-
ogies in the same space and would thus be experienced with navigating the regulatory landscape. 
An independent regulatory consultant will only be able to answer a certain percentage of questions 
(i.e., ~60%) and will therefore have to research some questions at a cost to the academic 
entrepreneur. Consequently, one benefit of working with larger consulting companies is the variety 
of internal consultants with expertise in many specific topics, which allows these companies to be 
more efficient, and they may end up costing less over time. In addition, independent consultants 
are at times willing to take equity shares as payment, while a larger company will not, as this can 
create conflicts of interest that limit the company’s ability to work with competing technologies. 
Prior to discussing device innovation or intellectual property with any consultant, the academic 
entrepreneur should contact their academic institution’s office of technology transfer to ensure the 
appropriate confidential disclosure agreement (CDA) or nondisclosure agreement (NDA) is gen-
erated and signed by both parties. 
 
Consulting costs may come in the form of hourly fees, ad hoc agreements (i.e., maximum budget 
set or not-to-exceed values), or pay-for-service contracts. As a general rule of thumb, brief 
discussions where nothing is in writing are free. If discussions are more complex and written 
deliverables are expected, then it is reasonable for a consultant to bill for services. In general, 
consultation costs for a full regulatory assessment for both the U.S. and the European Union range 
from $2,000 to $8,000, with an increase of ~$2,000–$4,000 for each additional geographic area or 
new country (see Table 1 for estimates of regulatory assessment costs).  
Conclusion 
Early in the process of medical device innovation, the academic entrepreneur must consider the 
regulatory pathway to get a product from the prototype stage to the market. Developing a realistic 
regulatory strategy should be done in a way that integrates other critical strategic components of 
the innovation process, including clinical, legal, research and development, reimbursement, engi-
neering, sales, and marketing domains. All of these components are based on the marketing claims 
in the regulatory application. By setting regulatory milestones that estimate the time and cost for 
each step, the academic entrepreneur and their team can understand the timeline for fundraising 
and necessary money infusion from the start. Different strategies may be possible for a specific 
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device, and the FDA encourages early and frequent contact, which can be essential for avoiding 
unexpected setbacks in the approval process. While the academic entrepreneur may think it 
possible to do it alone, early consultation with regulatory experts, despite the initial upfront cost, 
can save significant time and money in the long run.  
 
Table 1. Regulatory Assessment Cost Estimates. 
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Resources 
1. Biodesign: The Process of Innovating Medical Technologies 
a. In the book Biodesign: The Process of Innovating Medical Technologies, written 
by Paul Yock, Stefanos Zenios, and Josh Makower, the chapter “5.4 Regulatory 
Strategy” presents an excellent overview of regulatory pathways in the U.S. and 
worldwide, especially in the European Union, Canada, China, India, and Japan. 
b. Book available on Amazon: https://www.amazon.com/Biodesign-Process-
Innovating-Medical-
Technologies/dp/110708735X/ref=sr_1_1?s=books&ie=UTF8&qid=1517864373
&sr=1-
1&keywords=Biodesign%3A+The+Process+of+Innovating+Medical+Technologi
es.  
c. Book’s accompanying website: http://ebiodesign.org/.  
2. Pre-submissions and Meetings with FDA Staff 
a.  The presentation “Pre-submissions and Meetings with FDA Staff” by the U.S. 
Food and Drug Administration is an extremely helpful guide on the pre-
submission or Q-sub process—the types of meetings and how and when to request 
them. It also includes a list of best practices for meeting with the FDA at the end 
of the powerpoint. 
b. Presentation available 
here:https://www.fda.gov/downloads/Training/CDRHLearn/UCM387291.pdf. 
3. Product Classification Database 
a. The Product Classification Database hosted by the U.S. Food and Drug 
Administration and the Department of Health and Human Services is an important 
resource to utilize early during device ideation or development. It allows users to 
identify the classifications of current devices on the market to use as a guide for 
the likely classification of their new device.  
b. Database available here:
 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cf
m. 
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